Rituximab and hyaluronidase human, recombinant (Subcutaneous)
Medically reviewed by Drugs.com. Last updated on Dec 26, 2021.
Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab-containing products, including rituximab and hyaluronidase human, recombinant. Hepatitis B Virus (HBV) reactivation can occur in patients treated with rituximab-containing products, including rituximab and hyaluronidase human, recombinant, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with rituximab and hyaluronidase human, recombinant. Discontinue rituximab and hyaluronidase human, recombinant and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab-containing products, including rituximab and hyaluronidase human, recombinant .
Commonly used brand name(s)
In the U.S.
- Rituxan Hycela
Available Dosage Forms:
- Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Monoclonal Antibody
Uses for rituximab and hyaluronidase human, recombinant
Rituximab and hyaluronidase human, recombinant combination injection is used alone or together with other cancer medicines to treat follicular lymphoma and chronic lymphocytic leukemia (CLL). It is also used together with other medicines to treat diffuse large B-cell lymphoma (DLBCL) in people who have not received previous treatment.
Rituximab and hyaluronidase human, recombinant combination injection is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
Rituximab and hyaluronidase human, recombinant is to be given only by or under the direct supervision of your doctor.
Before using rituximab and hyaluronidase human, recombinant
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For rituximab and hyaluronidase human, recombinant, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to rituximab and hyaluronidase human, recombinant or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of rituximab and hyaluronidase human, recombinant combination injection in children. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of rituximab and hyaluronidase human, recombinant combination injection in the elderly. However, elderly patients are more sensitive to the effects of rituximab and hyaluronidase human, recombinant than younger adults.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during bre..
